Alterations in innate immune defense distinguish first-episode schizophrenia patients from healthy controls.

Chen, Song; Gou, Mengzhuang; Chen, Wenjin; Xiu, Meihong; Fan, Hongzhen; Tan, Yunlong; Tian, Li

Chen, Song; Gou, Mengzhuang; Chen, Wenjin; Xiu, Meihong; Fan, Hongzhen; Tan, Yunlong; Tian, Li.

Afiliación

Chen S; Peking University HuiLongGuan Clinical Medical School, Beijing HuiLongGuan Hospital, Beijing, China.
Gou M; Peking University HuiLongGuan Clinical Medical School, Beijing HuiLongGuan Hospital, Beijing, China.
Chen W; Peking University HuiLongGuan Clinical Medical School, Beijing HuiLongGuan Hospital, Beijing, China.
Xiu M; Peking University HuiLongGuan Clinical Medical School, Beijing HuiLongGuan Hospital, Beijing, China.
Fan H; Peking University HuiLongGuan Clinical Medical School, Beijing HuiLongGuan Hospital, Beijing, China.
Tan Y; Peking University HuiLongGuan Clinical Medical School, Beijing HuiLongGuan Hospital, Beijing, China.
Tian L; Department of Physiology, Faculty of Medicine, Institute of Biomedicine and Translational Medicine, University of Tartu, Tartu, Estonia.

Front Psychiatry ; 13: 1024299, 2022.

Article en En | MEDLINE | ID: mdl-36311523

Palabras clave

biomarker; complement component 4; endotoxin; first-episode schizophrenia (FES); high mobility group box 1 protein (HMGB1)

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: Front Psychiatry Año: 2022 Tipo del documento: Article País de afiliación: China

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google